Overall, our data indicate that the JAK-STAT pathway, more specifically the activation of JAK1-JAK2 and STAT1, acts as a brake in the osteogenic trans-differentiation of VSMCs induced by hyperphosphatemia. The gene discussed is JAK2; the disease is hyperphosphatemia.